Immunovant, Inc.
Immunovant, Inc. (IMVT) Revenue
Annual & quarterly revenue history · segment & region breakdown
IMVT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsImmunovant, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2026.
Revenue trend
2026 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2026-03-31 | $0.00B | +$0.00B | — |
| 2025-03-31 | $0.00B | +$0.00B | — |
| 2024-03-31 | $0.00B | +$0.00B | — |
| 2023-03-31 | $0.00B | +$0.00B | — |
| 2022-03-31 | $0.00B | +$0.00B | — |
| 2021-03-31 | $0.00B | +$0.00B | — |
| 2020-03-31 | $0.00B | +$0.00B | — |
| 2019-03-31 | $0.00B | +$0.00B | — |
| 2018-03-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare IMVT revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Immunovant, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Immunovant, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Immunovant, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IMVT revenue · 4 questionsIMVT's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2026.
▸ Source: FMP · Immunovant, Inc. SEC filings · GAAP · Immunovant, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026